Material Adverse Change (MAC)

Specialty pharmacy updates for Empire BlueCross BlueShield are listed below.

 

Prior authorization clinical review of nononcology use of specialty pharmacy drugs is managed by Empire’s Medical Specialty Drug Review team. Review of specialty pharmacy drugs for oncology use is managed by AIM Specialty Health® (AIM), a separate company.

 

Inclusion of the National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a not otherwise classified (NOC) code.

 

Step therapy updates

Clinical Criteria ING-CC-0182 currently has a step therapy preferring Ferrlecit®, Infed®, and Venofer®.

 

Effective for dates of service on and after March 1, 2023, the status of Infed in current criteria documents will be changing in our existing specialty pharmacy medical step therapy review process. This update is to notify that Infed will change to non-preferred.

 

Also, effective for dates of service on or after December 1, 2022, Feraheme® (ferumoxytol) will change to preferred for both brand and generic.

 

Access our Clinical Criteria to view the complete information for these step therapy updates.

 

Clinical Criteria

Status

Drug

HCPCS or CPT® code(s)

ING-CC-0182

Nonpreferred

Infed (iron dextran)

J1750

ING-CC-0182

Nonpreferred

Injectafer® (ferric carboxymaltose)

J1439

ING-CC-0182

Nonpreferred

Monoferric® (ferric derisomaltose)

J1437

ING-CC-0182

Preferred

Feraheme (ferumoxytol)

Q0138

ING-CC-0182

Preferred

Ferrlecit (sodium ferric gluconate/sucrose complex)

J2916

ING-CC-0182

Preferred

Venofer® (iron sucrose)

J1756

 

NYBCBS-CM-012641-22-CPN12421



Featured In:
December 2022 Newsletter